Guangdong Xinbao Pharmaceutical Technology Co., Ltd.

Guangdong Xinbao Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Xinbao Pharmaceutical") was established in 2009, and is a modern Chinese medicine pharmaceutical enterprise focusing on the research and development, production, and sales of Chinese patent medicines. The company is rooted in therapeutic fields such as cardiovascular and cerebrovascular diseases, respiratory diseases, and digestive diseases, with pharmaceutical manufacturing as its core business. Adhering to a development path driven by both research and innovation and marketing innovation, it has gradually formed a sustainable business system based on Chinese patent medicines and innovative products for the greater health industry.
Xinbao Pharmaceutical has been deeply engaged in the key field of biomedicine for 13 years. It mainly produces more than ten varieties in dosage forms such as pills, tablets, capsules, and granules. Among them, its four main products, Xinbao Pills, Guilu Bushen Tablets, Pudilan Xiaoyan Tablets, and Pudilan Xiaoyan Capsules, are all high-tech products of Guangdong Province, with leading market shares. The leading product, Xinbao Pills, as a brand Chinese patent medicine for the treatment of bradycardia and a multifunctional cardiac medicine for simultaneous treatment of heart and kidney, has advantages such as broad indications, significant efficacy, and few side effects. It has won honors including the Third Prize of the National Science and Technology Progress Award, the National Secondary Protected Variety of Traditional Chinese Medicine, the Second Prize of Guangdong Provincial Science and Technology Progress Award, and the Guangdong Provincial Famous High-Tech Product. It has been selling well for over 30 years, benefiting more than 100 million heart disease patients, and is known as the "Chinese Heart-Rescue Pill". Guilu Bushen Tablets is a characteristic kidney-tonifying product that tonifies both yin and yang. Once launched, it became an incremental tonic product in chain terminals. In 2017, famous products such as Xinbao Pills and Guilu Bushen Tablets were selected into the textbook "Clinical Traditional Chinese Medicine". As a planned textbook for the 13th Five-Year Plan of regular higher education, it is a required course for students in medical and pharmaceutical colleges across the country. The heat-clearing and detoxifying series products, Pudilan Xiaoyan Tablets and Pudilan Xiaoyan Capsules, have become the leading brand of "traditional Chinese medicine antibiotics" due to excellent product quality and good efficacy. During the COVID-19 pandemic in 2020, Xingchen brand Pudilan Xiaoyan series products were repeatedly included in the traditional Chinese medicine prevention and treatment plans for pneumonia in multiple provinces and were listed as recommended drugs for epidemic prevention.
In 2011, seizing the opportunity of Chinese medicine modernization, Xinbao Pharmaceutical invested in the construction of a modern Chinese medicine production base in Guangzhou High-tech Industrial Development Zone, gradually forming a Chinese medicine industry chain with dual main series products for simultaneous treatment of heart and kidney and heat-clearing and detoxifying, combined with multiple potential small varieties. With the advancement of Chinese medicine modernization, the company has entered a new track of leapfrog development. In 2019, the company successively invested in the construction of the second-phase industry-university-research base and the third-phase greater health incubator, aiming to build a two-way joint cooperation model between the enterprise and universities in talent cultivation, scientific research and development, and transformation of technological achievements. At the same time, relying on the core geographical advantages of the Guangdong-Hong Kong-Macao Greater Bay Area, it strives to build a highland for greater health industry and research with "four new" features: innovation technology, innovation industry, innovation business format, and innovation model.
The company has always adhered to innovation-driven development. It is now a national high-tech enterprise, a specialized, refined, differentiated, and innovative SME of Guangdong Province, an innovative SME of Guangdong Province, and a demonstration enterprise of intellectual property in Guangdong Province. It has two provincial-level scientific research platforms: the Guangdong Provincial Engineering Technology Research Center for Xinbao Famous Quality Chinese Patent Medicines and the Guangdong Provincial Biomedical Science and Technology Collaborative Innovation Center. The company invests more than 10 million yuan in scientific research funding annually, dedicating to secondary development of Chinese patent medicines, process optimization, quality standard research, and development research of greater health products, continuously promoting the implementation and transformation of scientific research achievements. Currently, the company owns a total of 48 valid intellectual property items, has drafted or participated in the development of 4 national standards, and has won awards such as the Second Prize of the Science and Technology Award of the Chinese Association of Integrative Medicine and the First Prize of Guangdong Provincial Science and Technology Progress Award. At the same time, the company also attaches importance to the construction of enterprise management systems, and has successively passed certifications such as intellectual property management system certification, measurement management system certification, integration of informatization and industrialization management system certification, and cleaner production certification, continuously improving its quality management level.
The development of an enterprise cannot be separated from talents. The recruitment and cultivation of outstanding fresh graduates has always been an important strategy for talent development at Xinbao Pharmaceutical. Currently, Xinbao Pharmaceutical has more than 350 employees, involving 18 departments including production technology, quality management, research and development, finance, and marketing center.
Building a century-old Xinbao and benefiting all living beings is the company's vision and mission. The company always adheres to the business philosophy of "honesty and trustworthiness, win-win cooperation", carrying out benevolent hearts to make benevolent medicines, embracing virtuous hearts to attract talents, and emphasizing confidence for common development. By building an industry-university-research cooperation platform, gathering social elite talents, and building a century-old pharmaceutical enterprise integrating science, industry, and trade.
Welcome to follow our company's official WeChat account [Xinbao Pharmaceutical] to learn more about Xinbao news~